Since our inception, PEGUS has become an innovative leader in the Rx-to-OTC switch market. The PST model was originally a response to a gap in the safety research required for switching a medication from prescription to over-the-counter (OTC). It was a unique problem requiring an innovative solution. This solution opened a niche market that helped establish PEGUS and allowed it to expand its model and the company. This model led to designing a study to assist American Home Products (now Wyeth) in their efforts to switch Children's Advil.  PEGUS began work on two prospective observational studies of more than 44,000 children who received either Children's Advil or Children's Tylenol. Children's Advil was approved for OTC sale in 1996.


We have conducted PSTs for the treatment and/or prevention of herpes labialis (cold sores), high cholesterol, weight-loss, allergies, sleep, and a number of other medical conditions.  We designed and conducted the first actual use study in the United Kingdom in support of a successful switch.


PEGUS was the first research organization to use pharmacies to collect data in actual use studies, and we have created a large national network of sites consisting of a lead pharmacist and study staff trained in research methods that dedicate much of their time to conducting pharmaceutical research. We also developed a new model for the conduct of label comprehension studies to aid pharmaceutical firms in developing the best possible labeling for OTC medicines.


© PEGUS Research, Inc. 2016. Salt Lake City, Utah, United States. Tous droits réservés / All rights reserved.